MRK

Merck & Co., Inc. New York Stock Exchange
$76.58
Open: $76.17 High: $76.635 Low: $75.54 Close: $76.575
Range: 2021-06-23 - 2021-06-24
Volume: 13,156,935
Market: Open
Powered by Finage Stock APIDelayed data
MRK
Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth NJ, 7033 http://www.merck.com
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products.
  • CEO: Kenneth C. Frazier
  • Employees: 69,000
  • Sector: Healthcare
  • Industry: Drug Manufacturers
MRK News
Latest news about the MRK
  • ‘Unchecked spread in the U.S. is going to lead to other problems’: Doctor

    Dr. Anand Swaminathan, Emergency Medicine Physician in New Jersey, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

    View More →
  • A Covid underclass is forming

    Yahoo Finance’s Rick Newman reports vaccination disputes arising as return to work picks up steam.

    View More →
  • Merck Appoints Michael Klobuchar Chief Strategy Officer

    KENILWORTH, N.J., June 24, 2021--Merck Appoints Michael Klobuchar Chief Strategy Officer

    View More →
  • LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

    KENILWORTH, N.J., June 24, 2021--LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

    View More →
  • Merck (MRK) Dips More Than Broader Markets: What You Should Know

    Merck (MRK) closed at $75.58 in the latest trading session, marking a -0.8% move from the prior day.

    View More →
  • ‘Vaccination is very effective against the Delta variant’: Doctor

    Dr. Shereef Elnahal, University Hospital CEO and former NJDOH Commissioner, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

    View More →
  • Inpixon Secures Purchase Order for Implementation of Smart Office App with Multinational Mass Media and Entertainment Conglomerate

    Inpixon (Nasdaq: INPX), the Indoor Intelligence™ company, today announced that its smart office app, acquired in the recent The CXApp transaction, was selected by a globally recognized media and entertainment conglomerate with a portfolio of well-recognized movie, cable and network television, sports and news brands for implementation across multiple corporate campuses including its global headquarters.

    View More →
  • Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer

    KENILWORTH, N.J., Jun 22, 2021--Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of OS & PFS in Patients With Persistent, Recurrent or Metastatic Cervical Cancer

    View More →
  • Delta COVID-19 variant likely to become dominant U.S. strain: Doctor

    Dr. Susannah Hills, Pediatric Airway surgeon and assistant professor of ENT at Columbia University Medical Center, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

    View More →
  • Gov. Ducey’s decision to block COVID-19 policies for universities is ‘not based in science’: Doctor

    Dr. Hiral Tipirneni, Emergency Medicine Physician, joins Yahoo Finance Live to discuss to discuss the latest on the coronavirus pandemic.

    View More →
  • 10 Best Healthcare Stocks to Buy According to Hedge Funds

    In this article, we will take a look at some of the best healthcare stocks to buy based on the data of over 860 hedge funds tracked by Insider Monkey. You can skip our detailed analysis of the healthcare industry and go directly to see 5 Best Healthcare Stocks to Buy According to Hedge Funds. […]

    View More →
  • Affordable Care Act survives third Supreme Court challenge

    Andy Slavitt, former White House COVID-19 Response Team adviser, author of ‘PREVENTABLE: The Inside Story of How Leadership Failures, Politics, and Selfishness Doomed the U.S. Coronavirus Response’, joins Yahoo Finance to discuss the COVID-19 response in the U.S. and the Supreme court upholding the Affordable Care Act.

    View More →
  • Biden Administration Devotes Over $3.2B For Development Of Oral Antiviral Therapies For COVID-19: CNBC

    Officials on Thursday announced that the Biden Administration plans to invest more than $3.2 billion in developing antiviral medicines to treat COVID-19 and other viruses with pandemic potential, reported CNBC. The new program, dubbed Antiviral Program for Pandemics – is a "whole-of-government effort" that will speed up clinical trials of promising drug candidates and develop next-generation treatments for COVID-19 and other viruses that could cause future pandemics," said White House chief medi

    View More →
  • MSD Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19

    Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has entered into a procurement agreement with the United States government for Molnupiravir (MK-4482). Molnupiravir is currently being evaluated in a Phase 3 clinical trial, the MOVe-OUT study, for the treatment of non-hospitalized patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes. MSD is developing Molnupiravir in collaboration with Ridgeback Biot

    View More →
  • This Biopharma Giant May Have Just Found Its Ticket To Riches In the COVID-19 Market

    After a long year and a half spent enduring the coronavirus pandemic, signs of normalcy are starting to show in many U.S. businesses and communities, thanks in part to pharmaceutical breakthroughs including vaccines. After two previously failed attempts to develop new antiviral treatments, biopharma giant Merck (NYSE: MRK) has come up with something it believes will provide care for those in need. Specifically, Merck has been collaborating with Ridgeback Biotherapeutics on a clinical development program for molnupiravir, an oral antiviral medication.

    View More →
  • Merck to Participate in the Guggenheim Biopharma Strategy Series

    KENILWORTH, N.J., Jun 17, 2021--Merck to Participate in the Guggenheim Biopharma Strategy Series

    View More →
  • Influencers with Andy Serwer: David Ricks

    In this episode of Influencers, Eli Lilly Chairman & CEO David Ricks joins Andy to discuss the latest in the pharmaceutical industry, new progress in the fight against COVID-19, and potential groundbreaking advancements for the treatment of Alzheimer’s.

    View More →
  • COVID-19 pandemic is ‘far from over in other parts of the world’: Doctor

    Dr. Gustavo Ferrer, President of Aventura Pulmonary Institute, joins Yahoo Finance Live to discuss the latest on the coronavirus pandemic.

    View More →
  • 10 Best Dividend Stocks to Buy According to Billionaire Richard Chilton

    In this article, we discuss the 10 best dividend stocks to buy according to billionaire Richard Chilton. If you want to skip our detailed analysis of Chilton’s history and hedge fund performance, go directly to the 5 Best Dividend Stocks to Buy Now According to billionaire Richard Chilton. Note that all hedge fund data is […]

    View More →
  • FDA ‘shifting the bar’ for approval with new Alzheimer’s drug: Eli Lilly CEO

    Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss the FDA's approval of Biogen's new Alzheimer’s drug.

    View More →